

Guntram Schernthaner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8328765/publications.pdf>

Version: 2024-02-01

48
papers

7,120
citations

279798

23
h-index

189892

50
g-index

54
all docs

54
docs citations

54
times ranked

6613
citing authors

#	ARTICLE	IF	CITATIONS
1	Metformin and the heart: Update on mechanisms of cardiovascular protection with special reference to comorbid type 2 diabetes and heart failure. <i>Metabolism: Clinical and Experimental</i> , 2022, 130, 155-160.	3.4	24
2	Can glucose-lowering drugs affect the prognosis of COVID-19 in patients with type 2 diabetes?. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 251-252.	11.4	7
3	Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19 (<i>Diabetes Metab J</i> 2021;45:251-9). <i>Diabetes and Metabolism Journal</i> , 2021, 45, 615-616.	4.7	2
4	The management of type 2 diabetes before, during and after Covid-19 infection: what is the evidence?. <i>Cardiovascular Diabetology</i> , 2021, 20, 198.	6.8	8
5	The right place for metformin today. <i>Diabetes Research and Clinical Practice</i> , 2020, 159, 107946.	2.8	29
6	Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2020, 19, 185.	6.8	83
7	Cover Image, Volume 22, Issue 7. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, .	4.4	0
8	Sodium-glucose linked transporter-2 inhibitor renal outcome modification in type 2 diabetes: Evidence from studies in patients with high or low renal risk. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1024-1034.	4.4	6
9	Evidence from routine clinical practice: EMPRISE provides a new perspective on CVOTs. <i>Cardiovascular Diabetology</i> , 2019, 18, 115.	6.8	9
10	CARMELINA: An important piece of the DPP-4 inhibitor CVOT puzzle. <i>Diabetes Research and Clinical Practice</i> , 2019, 153, 30-40.	2.8	5
11	SGLT2 inhibitors in T2D and associated comorbidities – differentiating within the class. <i>BMC Endocrine Disorders</i> , 2019, 19, 64.	2.2	10
12	Frequency of Hypoglycaemia after Different Bariatric Surgical Procedures. <i>Obesity Facts</i> , 2019, 12, 397-406.	3.4	26
13	GLP-1 receptor agonists and cardiovascular risk in routine clinical practice. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 78-80.	11.4	1
14	Diabetes in the older patient: heterogeneity requires individualisation of therapeutic strategies. <i>Diabetologia</i> , 2018, 61, 1503-1516.	6.3	64
15	Prevalence of Micronutrient Deficiency in Patients with Morbid Obesity Before Bariatric Surgery. <i>Obesity Surgery</i> , 2018, 28, 643-648.	2.1	63
16	Unrecognised cardiovascular disease in type 2 diabetes: is it time to act earlier?. <i>Cardiovascular Diabetology</i> , 2018, 17, 145.	6.8	14
17	Advances in the management of cardiovascular risk for patients with type 2 diabetes: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes. <i>Therapeutics and Clinical Risk Management</i> , 2017, Volume 13, 69-79.	2.0	6
18	Translating recent results from the Cardiovascular Outcomes Trials into clinical practice: recommendations from the Central and Eastern European Diabetes Expert Group (CEEDEG). <i>Cardiovascular Diabetology</i> , 2017, 16, 137.	6.8	12

#	ARTICLE	IF	CITATIONS
19	Canagliflozin provides greater attainment of both HbA1c and body weight reduction versus sitagliptin in patients with type 2 diabetes. <i>Postgraduate Medicine</i> , 2016, 128, 725-730.	2.0	11
20	EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus. <i>Clinical Therapeutics</i> , 2016, 38, 1288-1298.	2.5	28
21	Is the Use of DPP-4 Inhibitors Associated With an Increased Risk for Heart Failure? Lessons From EXAMINE, SAVOR-TIMI 53, and TECOS. <i>Diabetes Care</i> , 2016, 39, S210-S218.	8.6	18
22	Combination therapy of SGLT2 inhibitors with incretin-based therapies for the treatment of type 2 diabetes mellitus: Effects and mechanisms of action. <i>Expert Review of Endocrinology and Metabolism</i> , 2016, 11, 281-296.	2.4	0
23	Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study. <i>Cardiovascular Diabetology</i> , 2015, 14, 116.	6.8	39
24	Risk of metformin use in patients with T2DM and advanced CKD. <i>Nature Reviews Endocrinology</i> , 2015, 11, 697-699.	9.6	12
25	The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system. <i>Diabetes and Vascular Disease Research</i> , 2014, 11, 306-323.	2.0	55
26	Lessons from SAVOR and EXAMINE: Some important answers, but many open questions. <i>Journal of Diabetes and Its Complications</i> , 2014, 28, 430-433.	2.3	13
27	Do We Still Need Pioglitazone for the Treatment of Type 2 Diabetes? A risk-benefit critique in 2013. <i>Diabetes Care</i> , 2013, 36, S155-S161.	8.6	86
28	Achieving glycemic control in patients with type 2 diabetes and renal impairment. <i>Acta Diabetologica</i> , 2013, 50, 283-291.	2.5	23
29	Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea. <i>Diabetes Care</i> , 2013, 36, 2508-2515.	8.6	429
30	Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial. <i>Lancet</i> , 2012, 379, 2270-2278.	13.7	138
31	Diabetes Mellitus in Older People: Position Statement on behalf of the International Association of Gerontology and Geriatrics (IAGG), the European Diabetes Working Party for Older People (EDWPOP), and the International Task Force of Experts in Diabetes. <i>Journal of the American Medical Directors Association</i> , 2012, 13, 497-502.	2.5	355
32	Hypoglycemia and Cardiovascular Risks. <i>Diabetes Care</i> , 2011, 34, S132-S137.	8.6	305
33	Kidney disease in diabetology: lessons from 2010. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 454-457.	0.7	8
34	Cure of Type 2 Diabetes by Metabolic Surgery? A Critical Analysis of the Evidence in 2010. <i>Diabetes Care</i> , 2011, 34, S355-S360.	8.6	24
35	Strict glycaemic control in diabetic patients with CKD or ESRD: beneficial or deadly?. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 2044-2047.	0.7	38
36	Ghrelin and Obestatin Levels in Severely Obese Women Before and After Weight Loss After Roux-en-Y Gastric Bypass Surgery. <i>Obesity Surgery</i> , 2009, 19, 29-35.	2.1	63

#	ARTICLE	IF	CITATIONS
37	YKL-40 is Elevated in Morbidly Obese Patients and Declines After Weight Loss. <i>Obesity Surgery</i> , 2009, 19, 1557-1563.	2.1	69
38	Kidney disease in diabetology: lessons from 2008. <i>Nephrology Dialysis Transplantation</i> , 2008, 24, 396-399.	0.7	11
39	Dual inhibition with losartan and aliskiren: a promising therapeutic option for type 2 diabetic nephropathy?. <i>Nature Clinical Practice Nephrology</i> , 2008, 4, 656-657.	2.0	9
40	Effect of Pioglitazone on Cardiovascular Outcome in Diabetes and Chronic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2008, 19, 182-187.	6.1	135
41	Kidney disease in diabetology: lessons from 2007. <i>Nephrology Dialysis Transplantation</i> , 2007, 23, 1112-1115.	0.7	14
42	Effects of Pioglitazone in Patients With Type 2 Diabetes With or Without Previous Stroke. <i>Stroke</i> , 2007, 38, 865-873.	2.0	459
43	Asymmetric Dimethylarginine Predicts Cardiovascular Events in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2007, 30, 1834-1839.	8.6	129
44	Metformin – from Devil to Angel. , 2007, , 77-86.		4
45	Hypertension and Diabetes. , 2007, , 417-436.		1
46	Effect of Massive Weight Loss induced by Bariatric Surgery on Serum Levels of Interleukin-18 and Monocyte-Chemoattractant-Protein-1 in Morbid Obesity. <i>Obesity Surgery</i> , 2006, 16, 709-715.	2.1	77
47	Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. <i>Lancet, The</i> , 2005, 366, 1279-1289.	13.7	3,840
48	Independent and Additive Impact of Blood Pressure Control and Angiotensin II Receptor Blockade on Renal Outcomes in the Irbesartan Diabetic Nephropathy Trial: Clinical Implications and Limitations. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 3027-3037.	6.1	341